# Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

> **NCT00002419** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 25 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Abacavir sulfate
- **DRUG:** Amprenavir
- **DRUG:** Efavirenz
- **DRUG:** Adefovir dipivoxil

## Key facts

- **NCT ID:** NCT00002419
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002419, "Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00002419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*